Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve outcomes in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
- MASLD and MASH are increasingly common liver diseases associated with obesity and type 2 diabetes.
- GLP-1 RAs could lead to weight loss and better blood sugar control.
- Improvements in liver fat content may occur with the use of GLP-1 RAs.
- The review examines both the effectiveness and safety of GLP-1 RAs in these liver conditions.
Simplified